MapLight Therapeutics (MPLT) Return on Capital Employed (2025)

MapLight Therapeutics (MPLT) reported Return on Capital Employed of 45.02% for Q4 2025.

MapLight Therapeutics (MPLT) Return on Capital Employed (2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 1 years of Return on Capital Employed data on file, last reported at 45.02% in Q4 2025.

For the quarter ending Q4 2025, Return on Capital Employed changed N/A year-over-year to 45.02%; the trailing twelve-month figure through Dec 2025 stood at 45.02% (changed N/A YoY), and the FY2025 full-year result was 57.91%, changed N/A from the prior year.
Return on Capital Employed held at 45.02% in Q4 2025.
In the past five years, Return on Capital Employed ranged from a high of 45.02% in Q4 2025 to a low of 45.02% in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-31.80%
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-107.40%
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	10.46%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	21.10%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	10.19%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-68.84%
10	MapLight Therapeutics	314.07 Mn	314.07 Mn	-	-45.02%

Historic Data

Download Data

Date	Value
Dec 31, 2025	-45.02%